logo
Book a meeting
Helixmith

Helixmith

Biotechnology, Pacific CTR Ct, Seoul, , 92121, California, 10390, United States, 51-200 Employees

helixmith.com

  • facebook
  • LinkedIn

phone no Phone Number: 85********

Who is HELIXMITH

Helixmith is a gene therapy company headquartered in Seoul, Korea, developing new and innovative biopharmaceuticals for previously untreated diseases, and is listed on KOSDAQ. The company...

Read More

lock icon Get Full Access
map
  • 10390 Pacific CTR Ct, Seoul, California, 92121, United States Headquarters: 10390 Pacific CTR Ct, Seoul, California, 92121, United States
  • 1996 Date Founded: 1996
  • 51-200 Employees: 51-200
  • dollar-icon Revenue: $1 Million to $5 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

checked-icon Does something look wrong? Fix it. | View contact records from HELIXMITH

Helixmith Org Chart and Mapping

Employees
Gina Pezzino

Gina Pezzino

Retired

Victor Harding

Victor Harding

Senior Clinical Project Manager

Gwen Everhart

Gwen Everhart

Clinical Data Manager

See Full Org Chart arrow
email-formate-icon
View Email Formats for Helixmith
arrow
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

Join Now

crown-icon Free credits every month

Frequently Asked Questions Regarding Helixmith

Answer: Helixmith's headquarters are located at Pacific CTR Ct, Seoul, , 92121, California, 10390, United States

Answer: Helixmith's phone number is 85********

Answer: Helixmith's official website is https://helixmith.com

Answer: Helixmith's revenue is $1 Million to $5 Million

Answer: Helixmith has 51-200 employees

Answer: Helixmith is in Biotechnology

Answer: Helixmith contact info: Phone number: 85******** Website: https://helixmith.com

Answer: Helixmith is a gene therapy company headquartered in Seoul, Korea, developing new and innovative biopharmaceuticals for previously untreated diseases, and is listed on KOSDAQ. The company has an extensive gene therapy pipeline, including a CAR-T program targeting several different types of solid tumors and an AAV vector program targeting neuromuscular diseases. Engensis (VM202), a more advanced pipeline candidate, is a plasmid DNA therapy being studied for DPN, diabetic foot ulcers, claudication, amyotrophic lateral sclerosis (Phase 2 beginning in late 2020), coronary artery disease and Charcot-Marie-Tooth disease. Helixmith clinical development activities are based in San Diego, California,

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access